Transgene Provides Q3 2019 Business Update, with Focus on Recently Announced Efficacy Results of TG4001

information fournie par Boursorama •14/11/2019 à 17:45

Transgene Provides Q3 2019 Business Update, with Focus on Recently Announced Efficacy Results of TG4001

* Promising TG4001 efficacy results presented at ESMO in September 2019
* €54 million in cash and cash equivalents as of September 30, 2019
* Significant news flow confirmed before year-end:
­ - First efficacy readout of TG4010 in lung cancer expected in December 2019
­ - myvac(TM): Two clinical trials with TG4050 to start shortly
­ - Start of clinical trial investigating new route of administration of TG6002

.../...